Innovation

Digital Health

Simple Charm positions AI beauty devices as a biotech-grade play

Topband-backed Simple Charm claims professional-grade precision for home beauty devices via AI facial recognition and ultrasonic technology.
Topband-backed Simple Charm claims professional-grade precision for home beauty devices via AI facial recognition and ultrasonic technology.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy

Tempest Therapeutics reports 100% CR rate in dual-targeting CAR-T trials

TPST-2003 achieved complete responses in all 15 CAR-T-naïve evaluable patients across two Phase 1 trials, with Tempest now targeting FDA talks on
TPST-2003 achieved complete responses in all 15 CAR-T-naïve evaluable patients across two Phase 1 trials, with Tempest now targeting FDA talks on
The Biotech Times Editorial Team  · 
Diagnostics
Regulatory Science

UroGen's ZUSDURI more than doubles revenue in Q1 2026

UroGen posted $29.2m in ZUSDURI sales in Q1 2026, up 109% quarter-on-quarter, as a permanent J Code unlocked broader reimbursement access.
UroGen posted $29.2m in ZUSDURI sales in Q1 2026, up 109% quarter-on-quarter, as a permanent J Code unlocked broader reimbursement access.
The Biotech Times Editorial Team  · 
Pharmaceuticals

Avalyn Pharma raises $300m in Nasdaq IPO for fibrosis drugs

The Boston-based clinical-stage biotech priced 16.7 million shares at $18 each to fund inhaled antifibrotic programmes targeting pulmonary fibrosis.
The Boston-based clinical-stage biotech priced 16.7 million shares at $18 each to fund inhaled antifibrotic programmes targeting pulmonary fibrosis.
The Biotech Times Editorial Team  · 
Bioprocessing
Cell & Gene Therapy

Cabaletta Bio signs 10-year cell therapy supply deal with Cellares

The agreement covers commercial-scale automated manufacture of rese-cel for autoimmune disease, with a BLA submission in myositis planned for 2027.
The agreement covers commercial-scale automated manufacture of rese-cel for autoimmune disease, with a BLA submission in myositis planned for 2027.
The Biotech Times Editorial Team  · 
Medical Devices
Regulatory Science

CorTec BCI implant enables stroke patient to control computer by thought

CorTec's Brain Interchange device delivered both stroke rehabilitation and thought-based computer control in one patient using identical implanted hardware.
CorTec's Brain Interchange device delivered both stroke rehabilitation and thought-based computer control in one patient using identical implanted hardware.
The Biotech Times Editorial Team  · 
Pharmaceuticals

Crescent Biopharma posts Q1 2026 results with $189m cash runway

The Waltham-based oncology biotech reported a $23.3m net loss and outlined data readouts from its CR-001 bispecific and two ADC programmes beginning
The Waltham-based oncology biotech reported a $23.3m net loss and outlined data readouts from its CR-001 bispecific and two ADC programmes beginning
The Biotech Times Editorial Team  · 
Medical Devices

Picard Medical and SynCardia featured in Mullings Group interview series

The NYSE-listed artificial heart maker used the two-part series to discuss its SynCardia device and next-generation Emperor platform.
The NYSE-listed artificial heart maker used the two-part series to discuss its SynCardia device and next-generation Emperor platform.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy

MW Does another test

its a long test to see what having a sponsored post looks like when publoshed.

A longer text on why we need this test adn what it looks like

Mark Walker  · 
Diagnostics
Digital Health

Ali Sheneamer Chief Business Development Officer at Bupa Arabia

Ali Sheneamer, Chief Business Development Officer at Bupa Arabia, introduced the Bupa Care Connect product, a healthcare solution aimed at improving patient care

Ali Sheneamer, Chief Business Development Officer at Bupa Arabia, introduced the Bupa Care Connect product, a digital-first healthcare solution aimed at improving patient care through connected services.

The Biotech Times Editorial Team  · 
Subscribe to Innovation